The COG SDC is responsible for all statistical and data operations within the COG. It also supports many of the administrative activities of the COG. The IT support required for all statistical and data center operations is also provided by the SDC grant.
The specific aims of the SDC are to: 1. Collaborate on the development of the COG's scientific agenda, as full members of Disease and Modality Committees 2. Provide leadership in the design of COG research, collaborating on the development of study pre-concepts, concepts, and protocols and providing study statistical considerations, includingsample size calculations and interim monitoringplans 3. Collaborate on the development of study case report forms used to collect the minimal data required for the evaluation of the study aims 4. Maintain a centralized remote data entry system to collect study data from COG institutions,resource centers, and reference laboratories, and maintainquality control procedures to assure the accuracy of COG research data 5. Monitor study data submitted by participating COG institutions,monitor the timeliness of data submissionand provide institutionswith expectancy and delinquencyreports, review submitted data, coordinate the collection and review of materials collected for modality reviews (pathology, surgery, radiation therapy), and coordinate study committee review of study data 6. Monitor study conduct, includingaccrual, patient safety, and study outcome;prepare public protocol progress reports for the COG and confidential reports of interim outcome data for the COG's Data Monitoring Committees 7. Collaborate on the production of abstracts and manuscripts reporting the results of COG science 8. Conduct research on statistical methods that have direct relevance to COG's research goals and conduct special analyses (e.g., on prognostic factors, outcome for specific patient subsets, etc.), taking advantage of the wealth of information contained in the group's research databases 9. Provide statistical collaboration for the COG's correlative laboratory research agenda. 10. Collaborate with members of the Group Operations Center in the completion of various administrative activities, including institutional audits and institutional performance monitoring 11. Provide education and training to the Group membership, including collaboration on the trainingof new study chairs, collaboration on new and continuingeducation training for institutionalclinical research associates and presentations on statistical issues of interest to the Group membership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA098413-07S1
Application #
7931114
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
2003-06-20
Project End
2012-02-29
Budget Start
2009-09-01
Budget End
2012-02-29
Support Year
7
Fiscal Year
2009
Total Cost
$684,650
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Dix, David B; Seibel, Nita L; Chi, Yueh-Yun et al. (2018) Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 36:1564-1570
Fernandez, Conrad V; Mullen, Elizabeth A; Chi, Yueh-Yun et al. (2018) Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol 36:254-261
Rau, Rachel E; Dreyer, ZoAnn; Choi, Mi Rim et al. (2018) Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer 65:
Burke, Michael J; Devidas, Meenakshi; Maloney, Kelly et al. (2018) Severe pegaspargase hypersensitivity reaction rates (grade ?3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma 59:1624-1633
Urtishak, Karen A; Wang, Li-San; Culjkovic-Kraljacic, Biljana et al. (2018) Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene :
Ariƫs, Ingrid M; Bodaar, Kimberly; Karim, Salmaan A et al. (2018) PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med 215:3094-3114
Gupta, Sumit; Devidas, Meenakshi; Loh, Mignon L et al. (2018) Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). Leukemia 32:1370-1379
Malempati, Suman; Weigel, Brenda J; Chi, Yueh-Yun et al. (2018) The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer :
Mansour, Marc R; He, Shuning; Li, Zhaodong et al. (2018) JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. J Exp Med 215:1929-1945
Slayton, William B; Schultz, Kirk R; Kairalla, John A et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 36:2306-2314

Showing the most recent 10 out of 473 publications